Lupin launches plaque psoriasis treatment spray in US market
New Delhi: Drug major Lupin announced the launch of Desoximetasone Topical Spray, used for the treatment of plaque psoriasis, in the US market.
"Lupin's Desoximetasone Topical Spray, 0.25 percent, is the generic equivalent of Taro Pharmaceuticals U.S.A Inc.'s Topicort Topical Spray, 0.25 percent.
It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older," the company said in a regulatory filing.
Quoting IQVIA MAT May 2018 data, Lupin said Desoximetasone Topical Spray, 0.25 percent, had annual sales of approximately USD 18.7 million in the US.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd